CR-001 IND cleared by U.S. FDA; Phase 1/2 ASCEND global clinical trial to evaluate CR-001 in first-line and previously treated patients on track to initiate in first quarter of 2026, with proof-of-concept data anticipated in first quarter of 2027 Crescent partner Kelun-Biotech receives IND approval for CR-003 (SKB105) by NMPA of China Four clinical trials across portfolio expected to initiate in 2026 WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (N ...

LAUSANNE, Switzerland, Jan. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 6,000 of the Company's common shares to a new employee on January 2, 2026 ("Grant"). The Grant was offered as material inducement to the employee's employment. The Grant was approved by the Compensation Committee of the Company's Board of Dire ...

Core Insights - The article addresses a frequently asked question regarding investment opportunities and strategies in the current market environment [1]. Group 1: Analyst Background - Leo Nelissen is an analyst specializing in economic developments related to supply chains, infrastructure, and commodities [2]. - He is a contributing author for iREIT®+HOYA Capital, focusing on providing insightful analysis and actionable investment ideas, particularly in dividend growth opportunities [2]. Group 2: Investment Position - The analyst has disclosed a beneficial long position in shares of AM, UNP, and RTX through various financial instruments [3].

Core Viewpoint - ADC Therapeutics is under investigation for potential securities fraud and unlawful business practices following a press release regarding clinical trial data that may have misrepresented adverse events [1][2]. Group 1: Investigation Details - Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics, focusing on whether the company and its officers engaged in securities fraud [1]. - The investigation is prompted by concerns over the company's recent disclosures and the implications for investors [1]. Group 2: Clinical Trial Data - On December 3, 2025, ADC Therapeutics announced updated data from the LOTIS-7 Phase 1b clinical trial for ZYNLONTA® in combination with glofitamab for patients with relapsed or refractory diffuse large B-cell lymphoma [2]. - The press release, while positive, noted adverse events in two patients, with one being treatment-related, and reported that cytokine release syndrome occurred in 36.7% of patients across dose levels [2]. Group 3: Stock Market Reaction - Following the announcement of the clinical trial data, ADC's stock price fell by $0.65 per share, representing a 14.13% decline, closing at $3.95 per share on December 3, 2025 [3].

Core Viewpoint - The article emphasizes the importance of the price at which quality companies are purchased, suggesting that this is a critical factor in successful investing [1]. Group 1 - The author identifies as a buy-and-hold investor focused on quality blue-chip stocks, Business Development Companies (BDCs), and Real Estate Investment Trusts (REITs) [1]. - The goal is to help lower and middle-class workers build investment portfolios consisting of high-quality, dividend-paying companies [1]. - The author aims to provide a new perspective to assist investors in achieving financial independence [1].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by ADC Therapeutics and its officers or directors, following a significant stock price drop after the release of clinical trial data [1][4]. Group 1: Investigation Details - Pomerantz LLP is representing investors of ADC Therapeutics and is urging them to contact the firm regarding the investigation [1]. - The investigation focuses on whether ADC Therapeutics has engaged in securities fraud or other unlawful business practices [1]. Group 2: Clinical Trial Data - On December 3, 2025, ADC Therapeutics announced updated data from the LOTIS-7 Phase 1b clinical trial for ZYNLONTA® in combination with glofitamab for patients with relapsed or refractory diffuse large B-cell lymphoma [3]. - The press release highlighted positive aspects of the data but also noted adverse events in two patients, with one being treatment-related, and reported that cytokine release syndrome occurred in 36.7% of patients across dose levels [3]. Group 3: Stock Price Reaction - Following the announcement of the clinical trial data, ADC Therapeutics' stock price fell by $0.65 per share, representing a 14.13% decrease, closing at $3.95 per share on December 3, 2025 [4].

Agree Realty Corporation (NYSE:ADC) is included among the 13 Highest Paying Monthly Dividend Stocks to Buy. Mizuho Modestly Adjusts Valuation on Agree Realty (ADC) Photo by Vitaly Taranov on Unsplash On December 17, Mizuho lowered its price target on Agree Realty to $75 from $77. The firm kept a Neutral rating on the stock. Agree Realty Corporation (NYSE:ADC) is a net-lease REIT that owns free-standing retail properties, including grocery stores, home improvement chains, dollar stores, and pharmacies. ...

Core Insights - Reaching retirement age presents both advantages and challenges for individuals relying on the U.S. system [1] Group 1 - The U.S. retirement system is a critical factor influencing financial stability for retirees [1] - Many individuals face uncertainty regarding their financial security upon reaching retirement age [1] - The balance between benefits and potential drawbacks of retirement age is a significant concern for the workforce [1]

Core Viewpoint - Agree Realty Corporation (ADC) is recognized as a high-quality and well-managed net lease retail REIT, boasting a diversified tenant base and a strong history of monthly dividend growth [1] Company Overview - ADC operates properties across the United States, indicating a broad geographical presence [1] - The company has established a solid track record in terms of dividend growth, which is a positive indicator for investors seeking income [1] Investment Focus - The analysis emphasizes the importance of researching various sectors, including commodities and technology, which can provide valuable insights for investment decisions [2] - The focus on metals and mining stocks, along with other industries such as consumer discretionary/staples, REITs, and utilities, highlights the diverse investment opportunities available [2]

Core Viewpoint - Agree Realty Corporation (ADC) is recognized as a high-quality and well-managed net lease retail REIT, boasting a diversified tenant base and a strong history of monthly dividend growth [1] Company Overview - Agree Realty Corporation operates properties across the United States, indicating a broad geographical presence [1] - The company has established a diversified tenant base, which can mitigate risks associated with reliance on a single sector or tenant [1] - The firm has a solid track record of consistent monthly dividend growth, appealing to income-focused investors [1]